<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7587964</article-id><article-id pub-id-type="doi">10.3390/molecules25204821</article-id><article-id pub-id-type="publisher-id">molecules-25-04821</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Chronological Review and Rational and Future Prospects of Cannabis-Based Drug Development</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Namdar</surname><given-names>Dvora</given-names></name><xref ref-type="aff" rid="af1-molecules-25-04821">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9500-7584</contrib-id><name><surname>Anis</surname><given-names>Omer</given-names></name><xref ref-type="aff" rid="af2-molecules-25-04821">2</xref></contrib><contrib contrib-type="author"><name><surname>Poulin</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="af3-molecules-25-04821">3</xref><xref ref-type="aff" rid="af4-molecules-25-04821">4</xref></contrib><contrib contrib-type="author"><name><surname>Koltai</surname><given-names>Hinanit</given-names></name><xref ref-type="aff" rid="af1-molecules-25-04821">1</xref><xref rid="c1-molecules-25-04821" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Busard&#x000f2;</surname><given-names>Francesco Paolo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-25-04821"><label>1</label>Institute of Plant Science, Agriculture Research Organization, Volcani Center, Rishon LeZion 7528809, Israel; <email>dvoran@volcani.agri.gov.il</email></aff><aff id="af2-molecules-25-04821"><label>2</label>Department of Urology, Sheba Medical Center, Ramat Gan 5262000, Israel; <email>omerwn@gmail.com</email></aff><aff id="af3-molecules-25-04821"><label>3</label>Consultant Patrick Poulin Inc., Qu&#x000e9;bec City, QC G1V 0A6, Canada; <email>patrick.poulin.4@umontreal.ca</email></aff><aff id="af4-molecules-25-04821"><label>4</label>School of Public Health, Universit&#x000e9; de Montr&#x000e9;al, Montr&#x000e9;al, QC H3T 1J4, Canada</aff><author-notes><corresp id="c1-molecules-25-04821"><label>*</label>Correspondence: <email>hkoltai@agri.gov.il</email>; Tel.: +972-3-9683039</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2020</year></pub-date><volume>25</volume><issue>20</issue><elocation-id>4821</elocation-id><history><date date-type="received"><day>30</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Despite the surge in cannabis chemistry research and its biological and medical activity, only a few cannabis-based pharmaceutical-grade drugs have been developed and marketed to date. Not many of these drugs are Food and Drug Administration (FDA)-approved, and some are still going through regulation processes. Active compounds including cannabinergic compounds (i.e., molecules targeted to modulate the endocannabinoid system) or phytocannabinoid analogues (cannabinoids produced by the plant) may be developed into single-molecule drugs. However, since in many cases treatment with whole-plant extract (whether as a solvent extraction, galenic preparation, or crude oil) is preferred over treatment with a single purified molecule, some more recently developed cannabis-derived drugs contain several molecules. Different combinations of active plant ingredients (API) from cannabis with proven synergies may be identified and developed as drugs to treat different medical conditions. However, possible negative effects between cannabis compounds should also be considered, as well as the effect of the cannabis treatment on the endocannabinoid system. FDA registration of single, few, or multiple molecules as drugs is a challenging process, and certain considerations that should be reviewed in this process, including issues of drug&#x02013;drug interactions, are also discussed here.</p></abstract><kwd-group><kwd>cannabis</kwd><kwd>cannabinergic</kwd><kwd>drug</kwd><kwd>FDA-approved</kwd><kwd>medical conditions</kwd><kwd>pharmaceutical-grade</kwd><kwd>phytocannabinoid</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-25-04821"><title>1. Introduction</title><sec id="sec1dot1-molecules-25-04821"><title>1.1. Motivation</title><p>This review aims to explore the chronology, as well as rational and future prospects, of cannabis-based drug development. The chronological path toward the development of cannabis-based drugs reflects the understanding and accumulating knowledge regarding active compounds and their mode of action. Translating these values into modern, registered, pharmaceutical drugs is a highly challenging task. For the scientific discussion below (see <xref ref-type="app" rid="app1-molecules-25-04821">Appendix A</xref> for methodology), we chose to include only peer-reviewed articles. In addition, we emphasize in this review cannabis drugs that have gone through legislation processes and registration as approved cannabis-related drugs. We use this list of drugs and scientific discussion to unveil the challenges and milestones that led us to the current situation in this arena, and then we further use this platform to draw outlines for future endeavors in this challenging field.</p></sec><sec id="sec1dot2-molecules-25-04821"><title>1.2. Basic Cannabis Chemotaxonomy</title><p>To date, only a few cannabis-based pharmaceutical grade medicines have been developed and marketed. A review of the market reveals that registered cannabis-based drugs follow the common, rather dated, dichotomous chemo-variation approach to <italic>Cannabis sativa</italic>, where only the relative contents of &#x00394;9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are considered [<xref rid="B1-molecules-25-04821" ref-type="bibr">1</xref>]. Under this rather simplistic chemotaxonomy, cannabis strains are divided into three main chemovars on the basis of the relative amounts of the two predominant phytocannabinoids (i.e., cannabinoids produced by the plant). These include chemovar I with high levels of THC (THC &#x0003e;50% of total phytocannabinoid content), the intermediate chemovar II strains with equal relative amounts of THC and CBD, and chemovar III strains producing CBD as the dominant phytocannabinoid [<xref rid="B1-molecules-25-04821" ref-type="bibr">1</xref>]. The basic cannabis chemotaxonomy gave grounds to the first drugs that were FDA-registered, as discussed below.</p></sec><sec id="sec1dot3-molecules-25-04821"><title>1.3. Brief Introduction to the Endocannabinoid System</title><p>The endocannabinoid system includes the cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2), their endogenous endocannabinoids ligands (<italic>N</italic>-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG), and the endocannabinoid metabolism enzymes [<xref rid="B2-molecules-25-04821" ref-type="bibr">2</xref>]. The latter include <italic>sn</italic>-1-specific diacylglycerol lipase-&#x003b1; (DGL&#x003b1;), DGL&#x003b2;, <italic>N</italic>-acyl-phosphatidylethanolaminehydrolysing phospholipase D (NAPE-PLD), monoacylglycerol lipase (MAGL; also known as MGL), and fatty-acid amide hydrolase 1 (FAAH) [<xref rid="B3-molecules-25-04821" ref-type="bibr">3</xref>]. The CB1 and CB2 receptors are G-protein-coupled receptors (GPCRs). CB1 is highly abundant in the brain, whereas CB2 is expressed mainly in immune cells but is also present at low levels in neuronal and non-neuronal brain cells [<xref rid="B3-molecules-25-04821" ref-type="bibr">3</xref>]. CB1 and CB2 signaling involves alterations in Cyclic adenosine monophosphate (cAMP) levels, Extracellular regulated kinase 1/2 (ERK1/2) phosphorylation, and &#x003b2;-arrestin-2 recruitment [<xref rid="B2-molecules-25-04821" ref-type="bibr">2</xref>]. They can also form heterodimers and lead to a biased agonistic response [<xref rid="B4-molecules-25-04821" ref-type="bibr">4</xref>]. Alterations in concentrations of the endogenous endocannabinoid ligands, receptor expression or activity, or endocannabinoid metabolic enzyme activity have been found to be associated with varied pathological conditions [<xref rid="B3-molecules-25-04821" ref-type="bibr">3</xref>].</p></sec><sec id="sec1dot4-molecules-25-04821"><title>1.4. Cannabinergic Compounds</title><p>Any molecule that modulates the endocannabinoid system, regardless of its chemical structure or pharmacological activity, is termed &#x0201c;cannabinergic&#x0201d; [<xref rid="B5-molecules-25-04821" ref-type="bibr">5</xref>]. The cannabinergic group of compounds includes CB1 or CB2 receptor ligands or blockers, substrates or inhibitors of fatty-acid amide hydrolase, and the endocannabinoid transporters. Studies of structure&#x02013;activity relationships between endocannabinoid receptors and many synthesized cannabinergic compounds (e.g., phytocannabinoid analogues and derivatives) have been performed, along with the determination of cannabinergic biological activities and pharmacokinetic properties [<xref rid="B6-molecules-25-04821" ref-type="bibr">6</xref>,<xref rid="B7-molecules-25-04821" ref-type="bibr">7</xref>,<xref rid="B8-molecules-25-04821" ref-type="bibr">8</xref>]. Cannabinergic compounds are considered as targets for the development of novel medications, e.g., for pain management [<xref rid="B7-molecules-25-04821" ref-type="bibr">7</xref>,<xref rid="B9-molecules-25-04821" ref-type="bibr">9</xref>] or as anti-inflammatory therapeutics [<xref rid="B10-molecules-25-04821" ref-type="bibr">10</xref>].</p></sec></sec><sec id="sec2-molecules-25-04821"><title>2. Chronology of Cannabis-Based Drug Development</title><sec id="sec2dot1-molecules-25-04821"><title>2.1. Drugs of One Molecule</title><sec id="sec2dot1dot1-molecules-25-04821"><title>2.1.1. Cannabis-&#x0201c;Inspired&#x0201d; Drugs</title><p>Using a synthetic compound over the purified phytocannabinoid reflects the desire to brand a drug as a non-plant material, yet &#x0201c;inspired&#x0201d; by plant compounds. The first registered drug, Marinol<sup>&#x000ae;</sup>, contains high amounts of dronabinol, the synthetic equivalent of THC (<xref rid="molecules-25-04821-t001" ref-type="table">Table 1</xref>). Marinol was registered and clinically tested for appetite stimulation and as an antiemetic. The antiemetic efficacy of Marinol was greatest in patients receiving cytotoxic therapy for Hodgkin&#x02019;s and non-Hodgkin&#x02019;s lymphomas. </p></sec><sec id="sec2dot1dot2-molecules-25-04821"><title>2.1.2. Cannabis-Derived Drugs</title><p>The second drug registered, Epidiolex<sup>&#x000ae;</sup>, contains high amounts of plant-derived CBD (<xref rid="molecules-25-04821-t001" ref-type="table">Table 1</xref>). Epidiolex, in development since 2002, was the first cannabis-derived drug approved by the United States US Food and Drug Administration (FDA) in 2018. The FDA granted approval of Epidiolex for the treatment of two rare and severe types of epilepsy&#x02014;Dravet syndrome and Lennox&#x02013;Gastaut [<xref rid="B11-molecules-25-04821" ref-type="bibr">11</xref>,<xref rid="B12-molecules-25-04821" ref-type="bibr">12</xref>]. Other single-molecule drugs, inspired by or based on cannabis, were approved for the treatment of different medical conditions including cancer-related pain relief, appetite stimulation, and nausea and vomiting associated with cancer chemotherapy (<xref rid="molecules-25-04821-t001" ref-type="table">Table 1</xref>). Recently, the FDA approved Epidiolex for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older [<xref rid="B13-molecules-25-04821" ref-type="bibr">13</xref>]. Pure CBD has been shown in multiple preclinical and clinical studies to benefit Alzheimer&#x02019;s disease (AD) and multiple sclerosis (MS) patients. CBD was also shown in preclinical and clinical studies to have antiepileptic activity and was suggested to benefit Parkinson&#x02019;s disease (PD) patients. However, more data are needed on the benefits of CBD activity for AD, MS, and PD patients [<xref rid="B14-molecules-25-04821" ref-type="bibr">14</xref>]. It should be noted that CBD usage carries some adverse side effects. CBD use in animal models led to developmental toxicity, whereas, in human models, CBD use was associated with several adverse effects including diarrhea, fatigue, vomiting, somnolence, and certain drug&#x02013;drug interactions (detailed below) [<xref rid="B15-molecules-25-04821" ref-type="bibr">15</xref>]. CBD toxicity and adverse effects should be stressed in light of the various marketing campaigns and anecdotal reports on the beneficial effects of CBD on multiple medical conditions, as well as the unregulated and ready availability of CBD products in some part of the world.</p></sec></sec><sec id="sec2dot2-molecules-25-04821"><title>2.2. Drugs of Combinatoric Formulations</title><p>Sativex, a GW Pharmaceuticals drug designated for pain relief with relative equal amounts of both THC and CBD and some terpenes (<xref rid="molecules-25-04821-t001" ref-type="table">Table 1</xref>), marked the updated notion of the power of plant-derived drugs based on the synergistic effect of different components. Sativex was targeted for the treatment of moderate to severe spasticity related with multiple sclerosis (MS). This is specifically in patients who have not responded sufficiently to other anti-spasticity medication. The results of a pivotal phase 3 trial suggested a successful Sativex therapy for this indication [<xref rid="B22-molecules-25-04821" ref-type="bibr">22</xref>]. In addition, Sativex was shown to be effective for the treatment of other medical conditions. For example, treatment with Sativex was demonstrated to markedly improve the frequency and severity of motor and vocal tics post treatment in treatment-resistant Tourette syndrome patients [<xref rid="B23-molecules-25-04821" ref-type="bibr">23</xref>]. Sativex is not yet approved by the FDA but it is registered for commercial distribution in Europe and Canada.</p></sec></sec><sec id="sec3-molecules-25-04821"><title>3. Taking Advantage of the &#x0201c;Entourage Effect&#x0201d;</title><p>For many centuries, plants and plant extracts were used as phytomedicines for therapeutic treatments for a vast variety of symptoms and medical conditions [<xref rid="B24-molecules-25-04821" ref-type="bibr">24</xref>]. Phytomedicines are based on the medical activity of active compounds present in plants. Moreover, in many cases, the biological effect of the whole-plant extract (solvent extraction, galenic preparation, or crude oil) was shown to have preferred activity over treatment with a single purified molecule. The enhancement of activity detected in phytomedicines was designated as the &#x0201c;entourage&#x0201d; effect [<xref rid="B25-molecules-25-04821" ref-type="bibr">25</xref>]. As detailed above, the idea behind drug development based on phytomedicines, like that of Marinol of GW pharmaceuticals, was to obtain the most abundant active compounds present in cannabis inflorescence and to mimic their activity using purified compounds administered in known dosages. However, different components present in plant extracts often promote the activity of the lead active compound(s) [<xref rid="B26-molecules-25-04821" ref-type="bibr">26</xref>]. Hence, the ability of the &#x0201c;entourage&#x0201d; effect to enhance medical activity should be examined.</p><p>One major difficulty with evaluating the entourage effect of traditional medicines is that the underlying mechanism of action is unresolved. In fact, traditional medicines in general and phytomedicines in particular assume this &#x0201c;entourage&#x0201d; as a concept or philosophy of therapy and, in many cases, strive to achieve it using a single-plant extract or some mixture of multiple plants. Some of the effects of compounds present in a given herbal preparation may be enhanced due to the cumulative activity of its constituents. In many other cases, the enhancement of activity by the combination of compounds may be at a synergistic level, as paired combinations of compounds exert effects that are more than the sum of their separate effects [<xref rid="B27-molecules-25-04821" ref-type="bibr">27</xref>]. Synergy may be based on enhanced bioavailability and ease of transport of active compounds across barriers, such as cell or organelle membranes, or enhanced protection of an active molecule from degradation by enzymes [<xref rid="B28-molecules-25-04821" ref-type="bibr">28</xref>]. Synergy may also result from the activation of more than one signaling pathway in the host cells, leading to an increased response [<xref rid="B29-molecules-25-04821" ref-type="bibr">29</xref>].</p><p>The &#x0201c;entourage effect&#x0201d; as the enhanced activity of combinations of phytocannabinoids was first recognized by Mechoulam and Ben-Shabat [<xref rid="B30-molecules-25-04821" ref-type="bibr">30</xref>]. We suggested that the &#x0201c;entourage effect&#x0201d; was one of the main motivations and considerations in the domestication of cannabis [<xref rid="B31-molecules-25-04821" ref-type="bibr">31</xref>]. Synergy in cannabis was recently demonstrated between phytocannabinoids [<xref rid="B32-molecules-25-04821" ref-type="bibr">32</xref>,<xref rid="B33-molecules-25-04821" ref-type="bibr">33</xref>] and further between phytocannabinoids and terpenes [<xref rid="B34-molecules-25-04821" ref-type="bibr">34</xref>]. Moreover, insight into the synergy between cannabis compounds was provided at the levels of both chemical composition and respective biological activity [<xref rid="B33-molecules-25-04821" ref-type="bibr">33</xref>,<xref rid="B35-molecules-25-04821" ref-type="bibr">35</xref>]. The identified synergistic interactions between cannabis molecules might be the &#x0201c;entourage effect&#x0201d; reported for cannabis preparations, as synergistic effects activate new biological pathways not activated by the components in isolation [<xref rid="B33-molecules-25-04821" ref-type="bibr">33</xref>,<xref rid="B35-molecules-25-04821" ref-type="bibr">35</xref>]. Importantly, herbal preparations of cannabis, cannabis varieties for use in medical preparations, and guidelines for prescribing doctors including physician&#x02019;s recommendations, dosages, and titration strategies were recently reviewed in [<xref rid="B36-molecules-25-04821" ref-type="bibr">36</xref>]. However, the incomplete understanding (for now) of the mechanism behind this &#x0201c;entourage effect&#x0201d; in cannabis preparations makes it difficult to follow regular drug development and approval procedures (discussed below).</p><p>Therefore, we suggest that the selection of combinations of highly active plant ingredients (APIs) from cannabis may open up new opportunities for drug development to treat various medical conditions [<xref rid="B31-molecules-25-04821" ref-type="bibr">31</xref>]. Identifying the APIs and their specific compositions within a plant extract, followed by the manufacture of a pure and quantifiable compositions, may lead to pharmaceutical drugs inspired by or based on only the beneficial compounds in cannabis for a certain medical condition. Importantly, these might be targeted to specific mechanisms involved with different diseases [<xref rid="B31-molecules-25-04821" ref-type="bibr">31</xref>,<xref rid="B33-molecules-25-04821" ref-type="bibr">33</xref>,<xref rid="B37-molecules-25-04821" ref-type="bibr">37</xref>].</p></sec><sec id="sec4-molecules-25-04821"><title>4. Other &#x0201c;Entourage&#x0201d; Considerations</title><sec id="sec4dot1-molecules-25-04821"><title>4.1. The &#x0201c;Parasitage Effect&#x0201d;</title><p>While the overwhelming richness of compounds in cannabis strains can enhance activity, they can also depress activity. In addition to the APIs for the treatment of a given condition, whole extracts (solvent extraction, galenic preparation, or crude oil) also contain other compounds which do not contribute to the desired biological or clinical effect. Moreover, in cases where activity is improved by selecting the most active fractions and eliminating parts of the whole extract, there is a general implication that there might also be negative molecular interactions. Indeed, it was found that the removal of antagonistic or nonactive compounds lowered the required concentrations of APIs [<xref rid="B33-molecules-25-04821" ref-type="bibr">33</xref>]. We call this phenomenon the &#x0201c;parasitage effect&#x0201d;; in physics, the term &#x0201c;parasitage&#x0201d; (<italic>French</italic>) describes destructive interference resulting from the interaction of coherent waves (for example) coming from the same source [<xref rid="B38-molecules-25-04821" ref-type="bibr">38</xref>]. We use this term here to describe the contra-&#x0201c;entourage effect&#x0201d;, a phenomenon in which certain coproduced compounds interfere with each other to diminish a chemo-biologic effect, instead of correlating to enhance it.</p><p>The &#x0201c;parasitage effect&#x0201d; of negative molecular interactions might result from the blockage of API-activated pathways. Cannabinoids target multiple receptors (e.g., CB1, CB2, transient receptor potential vanilloid receptor 1 (TRPV1)) [<xref rid="B39-molecules-25-04821" ref-type="bibr">39</xref>]. Hence, antagonistic interference with API receptor binding might also provide evidence for the existence of the parasitage effect. Yet, specific negative interactions between cannabis compounds should still be demonstrated and the mechanism explored.</p></sec><sec id="sec4dot2-molecules-25-04821"><title>4.2. Interaction between Endocannabinoids and Cannabinoids (Synthetic or Plant-Derived)</title><p>Some of the effects of phytocannabinoids involve modulation (activation/inhibition) of receptors and enzymes associated with the endocannabinoid system, which may suggest that at least part of the phytocannabinoid mode of action involves modulation of endocannabinoid activity [<xref rid="B40-molecules-25-04821" ref-type="bibr">40</xref>,<xref rid="B41-molecules-25-04821" ref-type="bibr">41</xref>]. For example, THC and its propyl synthetic analogue tetrahydrocannabivarin (THCV) are capable of binding with high affinity to CB1 and CB2 receptors [<xref rid="B39-molecules-25-04821" ref-type="bibr">39</xref>]. In another example, THC and non-THC phytocannabinoids activate and desensitize human heat-sensitive TRP channels of vanilloid type-1 (TRPV1). Anandamide is an endogenous agonist of TRPV1 [<xref rid="B40-molecules-25-04821" ref-type="bibr">40</xref>]. Since both endocannabinoids and phytocannabinoids activate the same receptor (TRPV1 in this case), phytocannabinoids may share activity exhibited by endocannabinoids acting via the endocannabinoid receptors [<xref rid="B40-molecules-25-04821" ref-type="bibr">40</xref>]. Phytocannabinoids may also alter endocannabinoid levels; CBD was shown to stimulate TRPV1 and, thus, inhibit anandamide uptake, leading to increased levels of endogenous AEA in an in vitro study [<xref rid="B42-molecules-25-04821" ref-type="bibr">42</xref>]. Phytocannabinoids were also shown to alter the activity of endocannabinoid enzymes; CBD in vivo treatment of the nude mouse xenograft model increased the activity of FAAH while decreasing anandamide content in tumor samples [<xref rid="B43-molecules-25-04821" ref-type="bibr">43</xref>]. However, the relevance of the interactions between phytocannabinoids and the endocannabinoid system to clinical uses needs to be further studied. Regardless, the effect on the endocannabinoid system by cannabis-inspired or cannabis-based drugs formulated from one or multiple molecules should be considered.</p></sec><sec id="sec4dot3-molecules-25-04821"><title>4.3. Degradation and Loss of Activation</title><p>Natural ratios of phytocannabinoids have been used as the basis for drug development. Several ratios found in plants display higher activity than others [<xref rid="B34-molecules-25-04821" ref-type="bibr">34</xref>]. When these phytocannabinoid ratios are altered, there is no enhancement of activity [<xref rid="B44-molecules-25-04821" ref-type="bibr">44</xref>]. Additionally, certain phytocannabinoids are more susceptive to degradation and more volatile than others [<xref rid="B45-molecules-25-04821" ref-type="bibr">45</xref>,<xref rid="B46-molecules-25-04821" ref-type="bibr">46</xref>]. Good manufacturing practices (GMP) should take into consideration the degradation of phytocannabinoids in medical-grade products to maintain the effective natural or established ratios and avoid substantial reduction in activity.</p></sec></sec><sec id="sec5-molecules-25-04821"><title>5. Drug&#x02013;Drug Interactions</title><p>A change in a drug&#x02019;s effect on the body when taken together with other drugs, such as common drug&#x02013;drug interactions (DDIs), should be considered more broadly since DDI may modulate efficacy versus toxicity. Most commonly, DDI results in adverse drug events, which may be caused from changes in pharmaceutical, pharmacokinetic, or pharmacodynamic properties. The interactions between plant-derived products and synthetic drugs (herein &#x0201c;drugs&#x0201d;) are based on the same pharmacokinetic and pharmacodynamic principles as DDIs. The studies of drug&#x02013;drug, food&#x02013;drug, and particularly plant-derived drug&#x02013;drug interactions and genetic factors affecting pharmacokinetics and pharmacodynamics are expected to improve drug safety and to enable personalized drug therapy. Attention is needed for interactions between plant-derived products and synthetic drugs (or naturally occurring chemicals) with a narrow therapeutic index (i.e., a narrow range of doses that confer effectivity without unacceptable adverse effects). However, to date, well-designed clinical studies evaluating herbal supplement&#x02013;drug interactions are limited; however, case reports are available [<xref rid="B47-molecules-25-04821" ref-type="bibr">47</xref>,<xref rid="B48-molecules-25-04821" ref-type="bibr">48</xref>,<xref rid="B49-molecules-25-04821" ref-type="bibr">49</xref>].</p><p>On the other hand, there are numerous in vitro and in vivo studies indicating that phytocannabinoid metabolism is mostly performed by the cytochrome P450 (CYP) isoenzymes. For example, CBD is metabolized by CYP 3A4 and 2C19 and to a lesser extent by CYP 2c8, 2C9, 1A2, 2C8, 2B6, and 2E1 [<xref rid="B50-molecules-25-04821" ref-type="bibr">50</xref>,<xref rid="B51-molecules-25-04821" ref-type="bibr">51</xref>]. This metabolism via CYP enzymes may inhibit or enhance their activity and, thus, affect the metabolism of various drugs, resulting in different DDI outcomes. In one case study, a threefold increase in tacrolimus levels was detected following the addition of CBD due to CYP3A4/5 inhibition. CBD also inhibits CYP2C19, and a threefold increase in levels of the active metabolite of clobazam has been reported [<xref rid="B52-molecules-25-04821" ref-type="bibr">52</xref>]. Interactions with other drugs metabolized by these isoenzymes should be anticipated.</p><p>In addition, CBD is a potent inhibitor of CYP2D6 [<xref rid="B53-molecules-25-04821" ref-type="bibr">53</xref>]. CYP2D6 metabolizes many antidepressants; thus, CBD may increase serum concentrations of selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, antipsychotics, beta blockers, and opioids (including codeine and oxycodone) [<xref rid="B54-molecules-25-04821" ref-type="bibr">54</xref>]. In contrast, any drug presenting an inhibiting or inducing effect on one of these enzymes may change CBD pharmacodynamics and, thus, affect CBD levels [<xref rid="B55-molecules-25-04821" ref-type="bibr">55</xref>]. These effects should be considered in the risk&#x02013;benefit assessment of CBD therapy, and patients and consumers should be made aware of the potential safety hazards of CBD use. Some CYP isoform activity is crucial for the endocannabinoid system. Cardiac CYP2J2 for example, which is inhibited by several phytocannabinoids, results in reduced metabolism of endogenous cardioprotective cannabinoids, such as anandamide [<xref rid="B56-molecules-25-04821" ref-type="bibr">56</xref>].</p><p>Overall, although further research on DDIs of CBD is needed, CBD may have serious interactions with drugs. It can affect the levels of other drugs, while its own level can be increased or decreased by other medications, and additive effects of CBD can occur with other drugs (e.g., in the case of painkillers).</p></sec><sec id="sec6-molecules-25-04821"><title>6. Registration Drugs: One Molecule or Combinatoric Formulations</title><p>There is a significant interest in the development of therapies and other consumer products derived from cannabis and its components, including CBD. Registering one, a few, or multiple molecules as drugs is a challenging task. Despite the synergistic effect of plant extracts over single compounds, traditional medicines based on whole plants, herbal extracts, or mixtures cannot be recognized as certified drugs as they are non-registerable [<xref rid="B36-molecules-25-04821" ref-type="bibr">36</xref>,<xref rid="B57-molecules-25-04821" ref-type="bibr">57</xref>]. Registerable drugs are based on known amounts of pure compounds, which can be synthesized and recombined and, thus, registered as formulated medicines. Chemical compositions of plant extracts are highly complex with up to hundreds of different components. Thus, their exact combination is not reproducible by plant growth according to the good manufacturing practices (GMP). Therefore, identifying active compounds in order to either purify or synthesize the determined active ingredients into effective and reproducible drugs is the focus of pharmaceutical companies.</p><p>Obviously, patients should have confidence in the drug&#x02019;s uniformity, strength, and consistent delivery that support appropriate dosing needed to treat patients with complex and serious conditions. This also applies to &#x0201c;combination products&#x0201d;. To that purpose, the FDA issued guidance for GMP requirements for combination products [<xref rid="B58-molecules-25-04821" ref-type="bibr">58</xref>], to codify the availability and quality of drugs, biologics, devices, and combination products that consistently meet applicable requirements and specifications both as combination products or as single drugs. Reasons for the rejection of combination products might include pharmacokinetics and/or pharmacodynamic interactions between the combined constituents, the effects of additional manufacturing steps, or other differences arising from combinations.</p><p>An FDA guideline was also issued on the regulation of cannabis and cannabis-derived products, including CBD. The FDA stated that it recognizes the potential opportunities that cannabis or cannabis-derived compounds may offer and acknowledges the significance of these possibilities. However, it is also aware of some companies that are marketing cannabis-derived compounds in violation of the Federal Food, Drug, and Cosmetic Act (FD&#x00026;C Act), and this marketing may put the health and safety of consumers at risk [<xref rid="B59-molecules-25-04821" ref-type="bibr">59</xref>].</p><p>The drug review and approval process generally contains several defined steps. <xref rid="molecules-25-04821-t002" ref-type="table">Table 2</xref> provides a brief summary of the Canadian Drug Review and Approval Process in accordance with the Food and Drugs Act (FDA), the Food and Drug Regulations (FDR), the related policies, and Health Canada guidelines, which are similar in most countries [<xref rid="B60-molecules-25-04821" ref-type="bibr">60</xref>]. Canada is the first G20 country to legalize cannabis on a national scale, for both recreational and medicinal purposes. Consequently, several biotech and big pharmaceutical companies have officially entered the Canadian cannabis industry to facilitate cannabis legalization and regulation in other countries.</p></sec><sec sec-type="conclusions" id="sec7-molecules-25-04821"><title>7. Conclusions and Future Prospects</title><p>Cannabis-based therapy is a powerful and promising tool as it takes advantage of an existing receptor system to affect multiple body systems and biological processes. However, as this sensitive and balanced endocannabinoids system serves other endogenous molecules and is also associated with drug metabolism, cannabis-based therapy must be carefully examined and applied.</p><p>As illustrated in <xref ref-type="fig" rid="molecules-25-04821-f001">Figure 1</xref>, cannabis-inspired drugs may be developed as synthetic cannabinoids or their derivatives. Cannabinergic drugs may also be developed to specifically attenuate components of the endocannabinoid system (e.g., endocannabinoid receptors). Cannabis-based drugs may be composed of one phytomolecule or as a combination of APIs from the plant. The activity of API combinations may be enhanced by taking advantage of the &#x0201c;entourage&#x0201d; and avoiding the &#x0201c;parasitage&#x0201d; effects. In any case, interaction(s) between endocannabinoids and cannabinoids (synthetic or plant-derived) or cannabinergic compounds must be examined, and steps for drug review should be taken and approval processes be followed, taking into consideration the need to register and approve drugs of combinatoric formulations.</p><p>As for the future, we appreciate the aspects involved in cannabis-based drug development, such as complex entourage effects and terpene considerations [<xref rid="B33-molecules-25-04821" ref-type="bibr">33</xref>,<xref rid="B34-molecules-25-04821" ref-type="bibr">34</xref>,<xref rid="B35-molecules-25-04821" ref-type="bibr">35</xref>,<xref rid="B36-molecules-25-04821" ref-type="bibr">36</xref>,<xref rid="B37-molecules-25-04821" ref-type="bibr">37</xref>]. We also acknowledge the current difficulties of the pharma industry to include natural preparations, as discussed above. However, significant efforts are ongoing in different research laboratories toward revealing the mechanisms and modes of action of other chemical constituents chaperoning the various cannabinoid(s) in whole extracts, such as terpenes and flavonoids. These attempts currently follow indications proved only at the cellular/tissue level. We believe that, as these attempts will bear fruit and the mode of action of the cannabinoids chaperons will be revealed, the pharmaceutical industry will follow these leads for the development of new generations of cannabis-based pharmaceutical products.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Zach Dunseth for English editing.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><app-group><app id="app1-molecules-25-04821"><title>Appendix A</title><p>Methodology: To reflect the challenging processes of translation of the accumulating knowledge regarding the active compounds and their mode of action into modern, registered, pharmaceutical drugs, a literature search was done using the following terms: &#x0201c;cannabis&#x0201d;, &#x0201c;<italic>Cannabis sativa</italic>&#x0201d;, &#x0201c;<italic>C. sativa</italic>&#x0201d;, &#x0201c;cannabinoids&#x0201d;, &#x0201c;terpenes&#x0201d;, &#x0201c;medical use&#x0201d;, &#x0201c;herbal preparations&#x0201d;, &#x0201c;hemp&#x0201d;, &#x0201c;oil&#x0201d;, &#x0201c;therapy&#x0201d;, &#x0201c;adverse effects&#x0201d;, &#x0201c;cannabis chemotaxonomy&#x0201d;, &#x0201c;endocannabinoid&#x0201d;, &#x0201c;cannabinergic compounds&#x0201d;, &#x0201c;entourage effect&#x0201d;, &#x0201c;parasitage&#x0201d;, &#x0201c;degradation&#x0201d;, &#x0201c;drug&#x02013;drug interactions&#x0201d;, and &#x0201c;drug registration&#x0201d;. The search was conducted on general and multidisciplinary research databases for peer-reviewed scientific manuscripts, such as PubMed, Google Scholar, Scopus, and Web of Science. Furthermore, a web search was carried out using the following websites for a non-exhaustive list of examples of medicines: US FDA, Canada&#x02019;s Food and Drugs Act, and The Drug Review and Approval Processes in Canada (updated to October 2020).</p></app></app-group><ref-list><title>References</title><ref id="B1-molecules-25-04821"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>E.</given-names></name><name><surname>Beckstead</surname><given-names>H.D.</given-names></name></person-group><article-title>Cannabinoid Phenotypes in Cannabis sativa</article-title><source>Nat. Cell Biol.</source><year>1973</year><volume>245</volume><fpage>147</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1038/245147a0</pub-id></element-citation></ref><ref id="B2-molecules-25-04821"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>A.C.</given-names></name><name><surname>Abood</surname><given-names>M.E.</given-names></name></person-group><article-title>CB 1 and CB 2 Receptor Pharmacology</article-title><source>Studies in Surface Science and Catalysis</source><publisher-name>Elsevier BV</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2017</year><volume>Volume 80</volume><fpage>169</fpage><lpage>206</lpage></element-citation></ref><ref id="B3-molecules-25-04821"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>New approaches and challenges to targeting the endocannabinoid system</article-title><source>Nat. Rev. Drug Discov.</source><year>2018</year><volume>17</volume><fpage>623</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1038/nrd.2018.115</pub-id><?supplied-pmid 30116049?><pub-id pub-id-type="pmid">30116049</pub-id></element-citation></ref><ref id="B4-molecules-25-04821"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>G.</given-names></name><name><surname>Varani</surname><given-names>K.</given-names></name><name><surname>Lillo</surname><given-names>A.</given-names></name><name><surname>Vincenzi</surname><given-names>F.</given-names></name><name><surname>Rivas-Santisteban</surname><given-names>R.</given-names></name><name><surname>Ra&#x000ef;ch</surname><given-names>I.</given-names></name><name><surname>Reyes-Resina</surname><given-names>I.</given-names></name><name><surname>Ferreiro-Vera</surname><given-names>C.</given-names></name><name><surname>Borea</surname><given-names>P.A.</given-names></name><name><surname>de Medina</surname><given-names>V.S.</given-names></name></person-group><article-title>Pharmacological data of cannabidiol-and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors</article-title><source>Pharmacol. Res.</source><year>2020</year><volume>159</volume><fpage>104940</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104940</pub-id><?supplied-pmid 32470563?><pub-id pub-id-type="pmid">32470563</pub-id></element-citation></ref><ref id="B5-molecules-25-04821"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goutopoulos</surname><given-names>A.</given-names></name><name><surname>Makriyannis</surname><given-names>A.</given-names></name></person-group><article-title>From cannabis to cannabinergics: New therapeutic opportunities</article-title><source>Pharmacol. Ther.</source><year>2002</year><volume>95</volume><fpage>103</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/S0163-7258(02)00250-4</pub-id><pub-id pub-id-type="pmid">12182958</pub-id></element-citation></ref><ref id="B6-molecules-25-04821"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>D.</given-names></name><name><surname>Meng</surname><given-names>Z.</given-names></name><name><surname>Thakur</surname><given-names>G.A.</given-names></name><name><surname>Fan</surname><given-names>P.</given-names></name><name><surname>Steed</surname><given-names>J.</given-names></name><name><surname>Tartal</surname><given-names>C.L.</given-names></name><name><surname>Hurst</surname><given-names>D.P.</given-names></name><name><surname>Reggio</surname><given-names>P.H.</given-names></name><name><surname>Deschamps</surname><given-names>J.R.</given-names></name><name><surname>Parrish</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Adamantyl Cannabinoids: A Novel Class of Cannabinergic Ligands</article-title><source>J. Med. Chem.</source><year>2005</year><volume>48</volume><fpage>4576</fpage><lpage>4585</lpage><pub-id pub-id-type="doi">10.1021/jm058175c</pub-id><?supplied-pmid 15999995?><pub-id pub-id-type="pmid">15999995</pub-id></element-citation></ref><ref id="B7-molecules-25-04821"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>N.R.</given-names></name><name><surname>Gomes</surname><given-names>F.V.</given-names></name><name><surname>Fonseca</surname><given-names>M.D.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Breuer</surname><given-names>A.</given-names></name><name><surname>Cunha</surname><given-names>T.M.</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>F.S.</given-names></name></person-group><article-title>Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative</article-title><source>Prog. Neuro Psychopharmacol. Biol. Psychiatry</source><year>2017</year><volume>79</volume><fpage>369</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.07.012</pub-id><?supplied-pmid 28720466?><pub-id pub-id-type="pmid">28720466</pub-id></element-citation></ref><ref id="B8-molecules-25-04821"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>S.</given-names></name><name><surname>Nikas</surname><given-names>S.P.</given-names></name><name><surname>Sharma</surname><given-names>R.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Paronis</surname><given-names>C.A.</given-names></name><name><surname>Leonard</surname><given-names>M.Z.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Honrao</surname><given-names>C.</given-names></name><name><surname>Mallipeddi</surname><given-names>S.</given-names></name><name><surname>Raghav</surname><given-names>J.G.</given-names></name><etal/></person-group><article-title>Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues</article-title><source>J. Med. Chem.</source><year>2016</year><volume>59</volume><fpage>6903</fpage><lpage>6919</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b00717</pub-id><pub-id pub-id-type="pmid">27367336</pub-id></element-citation></ref><ref id="B9-molecules-25-04821"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>S.K.</given-names></name></person-group><article-title>Cannabinergic Pain Medicine</article-title><source>Clin. J. Pain</source><year>2013</year><volume>29</volume><fpage>162</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1097/AJP.0b013e31824c5e4c</pub-id><pub-id pub-id-type="pmid">22367503</pub-id></element-citation></ref><ref id="B10-molecules-25-04821"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>D.</given-names></name><name><surname>Vemuri</surname><given-names>V.K.</given-names></name><name><surname>Duclos</surname><given-names>R.I.</given-names></name><name><surname>Makriyannis</surname><given-names>A.</given-names></name></person-group><article-title>The Cannabinergic System as a Target for Anti-inflammatory Therapies</article-title><source>Curr. Top. Med. Chem.</source><year>2006</year><volume>6</volume><fpage>1401</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.2174/15680266106061401</pub-id><pub-id pub-id-type="pmid">16918457</pub-id></element-citation></ref><ref id="B11-molecules-25-04821"><label>11.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name><surname>Felberbaum</surname><given-names>M.</given-names></name></person-group><article-title>FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms">https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-06-25">(accessed on 25 June 2018)</date-in-citation></element-citation></ref><ref id="B12-molecules-25-04821"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekar</surname><given-names>K.</given-names></name><name><surname>Pack</surname><given-names>A.</given-names></name></person-group><article-title>Epidiolex as adjunct therapy for treatment of refractory epilepsy: A comprehensive review with a focus on adverse effects</article-title><source>F1000Res</source><year>2019</year><volume>8</volume><fpage>234</fpage><pub-id pub-id-type="doi">10.12688/f1000research.16515.1</pub-id></element-citation></ref><ref id="B13-molecules-25-04821"><label>13.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name><surname>O&#x02019;Keefe</surname><given-names>L.</given-names></name></person-group><article-title>FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treat-seizures-rare">https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treat-seizures-rare</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-31">(accessed on 31 July 2020)</date-in-citation></element-citation></ref><ref id="B14-molecules-25-04821"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannucci</surname><given-names>C.</given-names></name><name><surname>Navarra</surname><given-names>M.</given-names></name><name><surname>Calapai</surname><given-names>F.</given-names></name><name><surname>Spagnolo</surname><given-names>E.V.</given-names></name><name><surname>Busard&#x000f2;</surname><given-names>F.P.</given-names></name><name><surname>Cas</surname><given-names>R.D.</given-names></name><name><surname>Ippolito</surname><given-names>F.M.</given-names></name><name><surname>Calapai</surname><given-names>G.</given-names></name></person-group><article-title>Neurological aspects of medical use of cannabidiol</article-title><source>CNS Neurol. Disord. Drug Targets</source><year>2017</year><volume>16</volume><fpage>541</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.2174/1871527316666170413114210</pub-id><?supplied-pmid 28412918?><pub-id pub-id-type="pmid">28412918</pub-id></element-citation></ref><ref id="B15-molecules-25-04821"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huestis</surname><given-names>M.A.</given-names></name><name><surname>Solimini</surname><given-names>R.</given-names></name><name><surname>Pichini</surname><given-names>S.</given-names></name><name><surname>Pacifici</surname><given-names>R.</given-names></name><name><surname>Carlier</surname><given-names>J.</given-names></name><name><surname>Busard&#x000f2;</surname><given-names>F.P.</given-names></name></person-group><article-title>Cannabidiol adverse effects and toxicity</article-title><source>Curr. Neuropharmacol.</source><year>2019</year><volume>17</volume><fpage>974</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.2174/1570159X17666190603171901</pub-id><?supplied-pmid 31161980?><pub-id pub-id-type="pmid">31161980</pub-id></element-citation></ref><ref id="B16-molecules-25-04821"><label>16.</label><element-citation publication-type="gov"><article-title>Marinol</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018651s021lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018651s021lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2004-09-15">(accessed on 15 September 2004)</date-in-citation></element-citation></ref><ref id="B17-molecules-25-04821"><label>17.</label><element-citation publication-type="gov"><article-title>EPIDIOLEX&#x000ae; (cannabidiol) oral solution, CX pending DEA scheduling action</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-06-10">(accessed on 10 June 2018)</date-in-citation></element-citation></ref><ref id="B18-molecules-25-04821"><label>18.</label><element-citation publication-type="gov"><article-title>SYNDROS (dronabinol) oral solution, CII</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205525s003lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205525s003lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-05-15">(accessed on 15 May 2017)</date-in-citation></element-citation></ref><ref id="B19-molecules-25-04821"><label>19.</label><element-citation publication-type="gov"><article-title>CESAMET&#x02122; (nabilone)</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2006-05-20">(accessed on 20 May 2006)</date-in-citation></element-citation></ref><ref id="B20-molecules-25-04821"><label>20.</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>J.</given-names></name></person-group><article-title>Phase 1 Trial of EB Cannabinol Cream Completes Treatment in Healthy Volunteers</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://epidermolysisbullosanews.com/2020/04/09/phase-1-trial-of-eb-cannabinol-cream-completes-treatment-in-healthy-volunteers">https://epidermolysisbullosanews.com/2020/04/09/phase-1-trial-of-eb-cannabinol-cream-completes-treatment-in-healthy-volunteers</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-04-09">(accessed on 9 April 2020)</date-in-citation></element-citation></ref><ref id="B21-molecules-25-04821"><label>21.</label><element-citation publication-type="web"><article-title>Sativex Oromucosal Spray</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/product/602/smpc">https://www.medicines.org.uk/emc/product/602/smpc</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-27">(accessed on 27 May 2020)</date-in-citation></element-citation></ref><ref id="B22-molecules-25-04821"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keating</surname><given-names>G.M.</given-names></name></person-group><article-title>Delta-9-tetrahydrocannabinol/cannabidiol oromucosal spray (Sativex<sup>&#x000ae;</sup>): A review in multiple sclerosis-related spasticity</article-title><source>Drugs</source><year>2017</year><volume>77</volume><fpage>563</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1007/s40265-017-0720-6</pub-id><?supplied-pmid 28293911?><pub-id pub-id-type="pmid">28293911</pub-id></element-citation></ref><ref id="B23-molecules-25-04821"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trainor</surname><given-names>D.</given-names></name><name><surname>Evans</surname><given-names>L.</given-names></name><name><surname>Bird</surname><given-names>R.</given-names></name></person-group><article-title>Severe motor and vocal tics controlled with Sativex<sup>&#x000ae;</sup></article-title><source>Australas Psychiatry</source><year>2016</year><volume>24</volume><fpage>541</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1177/1039856216663737</pub-id><?supplied-pmid 27558217?><pub-id pub-id-type="pmid">27558217</pub-id></element-citation></ref><ref id="B24-molecules-25-04821"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>S.Y.</given-names></name><name><surname>Litscher</surname><given-names>G.</given-names></name><name><surname>Gao</surname><given-names>S.H.</given-names></name><name><surname>Zhou</surname><given-names>S.F.</given-names></name><name><surname>Yu</surname><given-names>Z.L.</given-names></name><name><surname>Chen</surname><given-names>H.Q.</given-names></name><name><surname>Zhang</surname><given-names>S.F.</given-names></name><name><surname>Tang</surname><given-names>M.K.</given-names></name><name><surname>Sun</surname><given-names>J.N.</given-names></name><name><surname>Ko</surname><given-names>K.M.</given-names></name></person-group><article-title>Historical perspective of traditional indigenous medical practices: The current renaissance and conservation of herbal resources</article-title><source>Evid. Based Complement Alternat. Med.</source><year>2014</year><volume>2014</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1155/2014/525340</pub-id><?supplied-pmid 24872833?><pub-id pub-id-type="pmid">24872833</pub-id></element-citation></ref><ref id="B25-molecules-25-04821"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>S.</given-names></name></person-group><article-title>Whole organisms or pure compounds? Entourage effect versus drug specificity</article-title><source>Plant Medicines, Healing and Psychedelic Science</source><publisher-name>Springer Nature</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2018</year><fpage>133</fpage><lpage>149</lpage></element-citation></ref><ref id="B26-molecules-25-04821"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>E.M.</given-names></name></person-group><article-title>Synergy and other interactions in phytomedicines</article-title><source>Phytomedicine</source><year>2001</year><volume>8</volume><fpage>401</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1078/0944-7113-00060</pub-id><?supplied-pmid 11695885?><pub-id pub-id-type="pmid">11695885</pub-id></element-citation></ref><ref id="B27-molecules-25-04821"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odds</surname><given-names>F.C.</given-names></name></person-group><article-title>Synergy, antagonism, and what the chequerboard puts between them</article-title><source>J. Antimicrob. Chemother.</source><year>2003</year><volume>52</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1093/jac/dkg301</pub-id><pub-id pub-id-type="pmid">12805255</pub-id></element-citation></ref><ref id="B28-molecules-25-04821"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>B.</given-names></name><name><surname>Alves</surname><given-names>L.</given-names></name></person-group><article-title>Synergy in plant medicines</article-title><source>Curr. Med. Chem.</source><year>2003</year><volume>10</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.2174/0929867033368583</pub-id><pub-id pub-id-type="pmid">12570718</pub-id></element-citation></ref><ref id="B29-molecules-25-04821"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.-F.</given-names></name></person-group><article-title>Signaling cross-talk between TGF-&#x003b2;/BMP and other pathways</article-title><source>Cell Res.</source><year>2009</year><volume>19</volume><fpage>71</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/cr.2008.302</pub-id><pub-id pub-id-type="pmid">19002158</pub-id></element-citation></ref><ref id="B30-molecules-25-04821"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Ben-Shabat</surname><given-names>S.</given-names></name></person-group><article-title>From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: The ongoing story of cannabis</article-title><source>Nat. Prod. Rep.</source><year>1999</year><volume>16</volume><fpage>131</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1039/a703973e</pub-id><pub-id pub-id-type="pmid">10331283</pub-id></element-citation></ref><ref id="B31-molecules-25-04821"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koltai</surname><given-names>H.</given-names></name><name><surname>Namdar</surname><given-names>D.</given-names></name></person-group><article-title>Cannabis Phytomolecule &#x02019;Entourage&#x02019;: From Domestication to Medical Use</article-title><source>Trends Plant Sci.</source><year>2020</year><volume>25</volume><fpage>976</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1016/j.tplants.2020.04.007</pub-id><?supplied-pmid 32417167?><pub-id pub-id-type="pmid">32417167</pub-id></element-citation></ref><ref id="B32-molecules-25-04821"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>P.</given-names></name><name><surname>Futoran</surname><given-names>K.</given-names></name><name><surname>Lewitus</surname><given-names>G.M.</given-names></name><name><surname>Mukha</surname><given-names>D.</given-names></name><name><surname>Benami</surname><given-names>M.</given-names></name><name><surname>Shlomi</surname><given-names>T.</given-names></name><name><surname>Meiri</surname><given-names>D.</given-names></name></person-group><article-title>A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41598-018-32651-4</pub-id><?supplied-pmid 30250104?><pub-id pub-id-type="pmid">29311619</pub-id></element-citation></ref><ref id="B33-molecules-25-04821"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazuz</surname><given-names>M.</given-names></name><name><surname>Tiroler</surname><given-names>A.</given-names></name><name><surname>Moyal</surname><given-names>L.</given-names></name><name><surname>Hodak</surname><given-names>E.</given-names></name><name><surname>Nadarajan</surname><given-names>S.</given-names></name><name><surname>Vinayaka</surname><given-names>A.C.</given-names></name><name><surname>Gorovitz-Haris</surname><given-names>B.</given-names></name><name><surname>Lubin</surname><given-names>I.</given-names></name><name><surname>Drori</surname><given-names>A.</given-names></name><name><surname>Drori</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Synergistic cytotoxic activity of cannabinoids from <italic>Cannabis sativa</italic> against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo</article-title><source>Oncotarget</source><year>2020</year><volume>11</volume><fpage>1141</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.27528</pub-id><pub-id pub-id-type="pmid">32284791</pub-id></element-citation></ref><ref id="B34-molecules-25-04821"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namdar</surname><given-names>D.</given-names></name><name><surname>Voet</surname><given-names>H.</given-names></name><name><surname>Ajjampura</surname><given-names>V.</given-names></name><name><surname>Nadarajan</surname><given-names>S.</given-names></name><name><surname>Mayzlish-Gati</surname><given-names>E.</given-names></name><name><surname>Mazuz</surname><given-names>M.</given-names></name><name><surname>Shalev</surname><given-names>N.</given-names></name><name><surname>Koltai</surname><given-names>H.</given-names></name></person-group><article-title>Terpenoids and phytocannabinoids co-produced in Cannabis sativa strains show specific interaction for cell cytotoxic activity</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>3031</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24173031</pub-id><?supplied-pmid 31438532?><pub-id pub-id-type="pmid">31438532</pub-id></element-citation></ref><ref id="B35-molecules-25-04821"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nallathambi</surname><given-names>R.</given-names></name><name><surname>Mazuz</surname><given-names>M.</given-names></name><name><surname>Ion</surname><given-names>A.</given-names></name><name><surname>Selvaraj</surname><given-names>G.</given-names></name><name><surname>Weininger</surname><given-names>S.</given-names></name><name><surname>Fridlender</surname><given-names>M.</given-names></name><name><surname>Ahmad</surname><given-names>N.</given-names></name><name><surname>Sagee</surname><given-names>O.</given-names></name><name><surname>Kumari</surname><given-names>P.</given-names></name><name><surname>Nemichenizer</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Anti-inflammatory activity in colon models is derived from &#x003b4;9-tetrahydrocannabinolic acid that interacts with additional compounds in cannabis extracts</article-title><source>Cannabis Cannabinoid Res.</source><year>2017</year><volume>2</volume><fpage>167</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1089/can.2017.0027</pub-id><?supplied-pmid 29082314?><pub-id pub-id-type="pmid">29082314</pub-id></element-citation></ref><ref id="B36-molecules-25-04821"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunetti</surname><given-names>P.</given-names></name><name><surname>Pichini</surname><given-names>S.</given-names></name><name><surname>Pacifici</surname><given-names>R.</given-names></name><name><surname>Busard&#x000f2;</surname><given-names>F.P.</given-names></name><name><surname>del Rio</surname><given-names>A.</given-names></name></person-group><article-title>Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors</article-title><source>Medicina</source><year>2020</year><volume>56</volume><elocation-id>237</elocation-id><pub-id pub-id-type="doi">10.3390/medicina56050237</pub-id><?supplied-pmid 32429074?><pub-id pub-id-type="pmid">32429074</pub-id></element-citation></ref><ref id="B37-molecules-25-04821"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koltai</surname><given-names>H.</given-names></name><name><surname>Poulin</surname><given-names>P.</given-names></name><name><surname>Namdar</surname><given-names>D.</given-names></name></person-group><article-title>Promoting cannabis products to pharmaceutical drugs</article-title><source>Eur. J. Pharm. Sci.</source><year>2019</year><volume>132</volume><fpage>118</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2019.02.027</pub-id><pub-id pub-id-type="pmid">30851400</pub-id></element-citation></ref><ref id="B38-molecules-25-04821"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szarka</surname><given-names>L.</given-names></name></person-group><article-title>Geophysical aspects of man-made electromagnetic noise in the earth&#x02014;A review</article-title><source>Surv. Geophys.</source><year>1988</year><volume>9</volume><fpage>287</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1007/BF01901627</pub-id></element-citation></ref><ref id="B39-molecules-25-04821"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pertwee</surname><given-names>R.G.</given-names></name></person-group><article-title>The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: &#x00394;9-tetrahydrocannabinol, cannabidiol and &#x00394;9-tetrahydrocannabivarin</article-title><source>Br. J. Pharmacol.</source><year>2008</year><volume>153</volume><fpage>199</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0707442</pub-id><pub-id pub-id-type="pmid">17828291</pub-id></element-citation></ref><ref id="B40-molecules-25-04821"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>Piscitelli</surname><given-names>F.</given-names></name></person-group><article-title>The endocannabinoid system and its modulation by phytocannabinoids</article-title><source>Neurotherapeutics</source><year>2015</year><volume>12</volume><fpage>692</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1007/s13311-015-0374-6</pub-id><pub-id pub-id-type="pmid">26271952</pub-id></element-citation></ref><ref id="B41-molecules-25-04821"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corroon</surname><given-names>J.</given-names></name><name><surname>Felice</surname><given-names>J.F.</given-names></name></person-group><article-title>The endocannabinoid system and its modulation by cannabidiol (CBD)</article-title><source>Altern. Ther. Health Med.</source><year>2019</year><volume>25</volume><fpage>6</fpage><lpage>14</lpage><?supplied-pmid 31202198?><pub-id pub-id-type="pmid">31202198</pub-id></element-citation></ref><ref id="B42-molecules-25-04821"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisogno</surname><given-names>T.</given-names></name><name><surname>Hanu&#x00161;</surname><given-names>L.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Tchilibon</surname><given-names>S.</given-names></name><name><surname>Ponde</surname><given-names>D.E.</given-names></name><name><surname>Brandi</surname><given-names>I.</given-names></name><name><surname>Moriello</surname><given-names>A.S.</given-names></name><name><surname>Davis</surname><given-names>J.B.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide</article-title><source>Br. J. Pharmacol.</source><year>2001</year><volume>134</volume><fpage>845</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0704327</pub-id><?supplied-pmid 11606325?><pub-id pub-id-type="pmid">11606325</pub-id></element-citation></ref><ref id="B43-molecules-25-04821"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massi</surname><given-names>P.</given-names></name><name><surname>Valenti</surname><given-names>M.</given-names></name><name><surname>Vaccani</surname><given-names>A.</given-names></name><name><surname>Gasperi</surname><given-names>V.</given-names></name><name><surname>Perletti</surname><given-names>G.</given-names></name><name><surname>Marras</surname><given-names>E.</given-names></name><name><surname>Fezza</surname><given-names>F.</given-names></name><name><surname>Maccarrone</surname><given-names>M.</given-names></name><name><surname>Parolaro</surname><given-names>D.</given-names></name></person-group><article-title>5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid</article-title><source>J. Neurochem.</source><year>2008</year><volume>104</volume><fpage>1091</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.05073.x</pub-id><?supplied-pmid 18028339?><pub-id pub-id-type="pmid">18028339</pub-id></element-citation></ref><ref id="B44-molecules-25-04821"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blasco-Benito</surname><given-names>S.</given-names></name><name><surname>Seijo-Vila</surname><given-names>M.</given-names></name><name><surname>Caro-Villalobos</surname><given-names>M.</given-names></name><name><surname>Tundidor</surname><given-names>I.</given-names></name><name><surname>Andradas</surname><given-names>C.</given-names></name><name><surname>Garc&#x000ed;a-Taboada</surname><given-names>E.</given-names></name><name><surname>Wade</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>S.</given-names></name><name><surname>Guzm&#x000e1;n</surname><given-names>M.</given-names></name><name><surname>P&#x000e9;rez-G&#x000f3;mez</surname><given-names>E.</given-names></name></person-group><article-title>Appraising the &#x0201c;entourage effect&#x0201d;: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer</article-title><source>Biochem. Pharmacol.</source><year>2018</year><volume>157</volume><fpage>285</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2018.06.025</pub-id><pub-id pub-id-type="pmid">29940172</pub-id></element-citation></ref><ref id="B45-molecules-25-04821"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacifici</surname><given-names>R.</given-names></name><name><surname>Marchei</surname><given-names>E.</given-names></name><name><surname>Salvatore</surname><given-names>F.</given-names></name><name><surname>Guandalini</surname><given-names>L.</given-names></name><name><surname>Busard&#x000f2;</surname><given-names>F.P.</given-names></name><name><surname>Pichini</surname><given-names>S.</given-names></name></person-group><article-title>Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry</article-title><source>Clin. Chem. Lab Med.</source><year>2018</year><volume>56</volume><fpage>94</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1515/cclm-2017-0758</pub-id><pub-id pub-id-type="pmid">29176009</pub-id></element-citation></ref><ref id="B46-molecules-25-04821"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlovic</surname><given-names>R.</given-names></name><name><surname>Nenna</surname><given-names>G.</given-names></name><name><surname>Calvi</surname><given-names>L.</given-names></name><name><surname>Panseri</surname><given-names>S.</given-names></name><name><surname>Borgonovo</surname><given-names>G.</given-names></name><name><surname>Giupponi</surname><given-names>L.</given-names></name><name><surname>Cannazza</surname><given-names>G.</given-names></name><name><surname>Giorgi</surname><given-names>A.</given-names></name></person-group><article-title>Quality traits of &#x0201c;cannabidiol oils&#x0201d;: Cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>1230</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23051230</pub-id></element-citation></ref><ref id="B47-molecules-25-04821"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velez</surname><given-names>L.I.</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>E.</given-names></name><name><surname>Rice</surname><given-names>J.</given-names></name><name><surname>Benitez</surname><given-names>F.</given-names></name><name><surname>LoVecchio</surname><given-names>F.</given-names></name></person-group><article-title>Adverse reactions to cannabis and cannabinoids</article-title><source>Emerg. Med. Rep.</source><year>2018</year><volume>39</volume><fpage>20</fpage></element-citation></ref><ref id="B48-molecules-25-04821"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geller</surname><given-names>A.I.</given-names></name><name><surname>Shehab</surname><given-names>N.</given-names></name><name><surname>Weidle</surname><given-names>N.J.</given-names></name><name><surname>Lovegrove</surname><given-names>M.C.</given-names></name><name><surname>Wolpert</surname><given-names>B.J.</given-names></name><name><surname>Timbo</surname><given-names>B.B.</given-names></name><name><surname>Mozersky</surname><given-names>R.P.</given-names></name><name><surname>Budnitz</surname><given-names>D.S.</given-names></name></person-group><article-title>Emergency department visits for adverse events related to dietary supplements</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>1531</fpage><lpage>1540</lpage><pub-id pub-id-type="doi">10.1056/NEJMsa1504267</pub-id><pub-id pub-id-type="pmid">26465986</pub-id></element-citation></ref><ref id="B49-molecules-25-04821"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bushra</surname><given-names>A.</given-names></name><name><surname>Aslam</surname><given-names>N.</given-names></name><name><surname>Khan</surname><given-names>A.Y.</given-names></name></person-group><article-title>Food-Drug Interactions</article-title><source>Oman Med. J.</source><year>2011</year><volume>26</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.5001/omj.2011.21</pub-id><pub-id pub-id-type="pmid">22043389</pub-id></element-citation></ref><ref id="B50-molecules-25-04821"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>B.M.</given-names></name><name><surname>Correia-Da-Silva</surname><given-names>G.</given-names></name><name><surname>Teixeira</surname><given-names>N.</given-names></name></person-group><article-title>Inspired by Nature: Modern Medicines Derived from Cannabis</article-title><source>Front. Nat. Prod. Chem.</source><year>2018</year><volume>4</volume><fpage>119</fpage><lpage>155</lpage></element-citation></ref><ref id="B51-molecules-25-04821"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>R.</given-names></name><name><surname>Yamaori</surname><given-names>S.</given-names></name><name><surname>Takeda</surname><given-names>S.</given-names></name><name><surname>Yamamoto</surname><given-names>I.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name></person-group><article-title>Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes</article-title><source>Life Sci.</source><year>2011</year><volume>89</volume><fpage>165</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2011.05.018</pub-id><?supplied-pmid 21704641?><pub-id pub-id-type="pmid">21704641</pub-id></element-citation></ref><ref id="B52-molecules-25-04821"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoniou</surname><given-names>T.</given-names></name><name><surname>Bodkin</surname><given-names>J.</given-names></name><name><surname>Ho</surname><given-names>J.M.-W.</given-names></name></person-group><article-title>Drug interactions with cannabinoids</article-title><source>Can. Med Assoc. J.</source><year>2020</year><volume>192</volume><fpage>E206</fpage><pub-id pub-id-type="doi">10.1503/cmaj.191097</pub-id><?supplied-pmid 32122975?><pub-id pub-id-type="pmid">32122975</pub-id></element-citation></ref><ref id="B53-molecules-25-04821"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>R.</given-names></name><name><surname>Yamaori</surname><given-names>S.</given-names></name><name><surname>Okamoto</surname><given-names>Y.</given-names></name><name><surname>Yamamoto</surname><given-names>I.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name></person-group><article-title>Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19</article-title><source>Drug Metab. Pharmacokinet.</source><year>2013</year><volume>28</volume><fpage>332</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.2133/dmpk.DMPK-12-RG-129</pub-id><pub-id pub-id-type="pmid">23318708</pub-id></element-citation></ref><ref id="B54-molecules-25-04821"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>J.D.</given-names></name><name><surname>Winterstein</surname><given-names>A.G.</given-names></name></person-group><article-title>Potential Adverse Drug Events and Drug&#x02013;Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use</article-title><source>J. Clin. Med.</source><year>2019</year><volume>8</volume><elocation-id>989</elocation-id><pub-id pub-id-type="doi">10.3390/jcm8070989</pub-id></element-citation></ref><ref id="B55-molecules-25-04821"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsherbiny</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>C.G.</given-names></name></person-group><article-title>Medicinal Cannabis&#x02014;Potential Drug Interactions</article-title><source>Medicines</source><year>2018</year><volume>6</volume><elocation-id>3</elocation-id><pub-id pub-id-type="doi">10.3390/medicines6010003</pub-id><?supplied-pmid 30583596?><pub-id pub-id-type="pmid">30583596</pub-id></element-citation></ref><ref id="B56-molecules-25-04821"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>W.R.</given-names></name><name><surname>Weigle</surname><given-names>A.T.</given-names></name><name><surname>Das</surname><given-names>A.</given-names></name></person-group><article-title>Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2</article-title><source>J. Inorg. Biochem.</source><year>2018</year><volume>184</volume><fpage>88</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2018.03.016</pub-id><pub-id pub-id-type="pmid">29689453</pub-id></element-citation></ref><ref id="B57-molecules-25-04821"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettiol</surname><given-names>A.</given-names></name><name><surname>Lombardi</surname><given-names>N.</given-names></name><name><surname>Crescioli</surname><given-names>G.</given-names></name><name><surname>Maggini</surname><given-names>V.</given-names></name><name><surname>Gallo</surname><given-names>E.</given-names></name><name><surname>Mugelli</surname><given-names>A.</given-names></name><name><surname>Firenzuoli</surname><given-names>F.</given-names></name><name><surname>Baronti</surname><given-names>R.</given-names></name><name><surname>Vannacci</surname><given-names>A.</given-names></name></person-group><article-title>Galenic Preparations of Therapeutic Cannabis sativa Differ in Cannabinoids Concentration: A Quantitative Analysis of Variability and Possible Clinical Implications</article-title><source>Front. Pharmacol.</source><year>2019</year><volume>9</volume><pub-id pub-id-type="doi">10.3389/fphar.2018.01543</pub-id></element-citation></ref><ref id="B58-molecules-25-04821"><label>58.</label><element-citation publication-type="gov"><article-title>Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products. Final guidance, January 2017, U.S. Department of Health and Human Services, Food and Drug Administration</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-requirements-combination-products">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-requirements-combination-products</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-01-18">(accessed on 18 January 2017)</date-in-citation></element-citation></ref><ref id="B59-molecules-25-04821"><label>59.</label><element-citation publication-type="gov"><article-title>FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd">https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-01-10">(accessed on 10 January 2020)</date-in-citation></element-citation></ref><ref id="B60-molecules-25-04821"><label>60.</label><element-citation publication-type="web"><article-title>The drug review and approval process in Canada. An e-guide</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://spharm-inc.com/the-drug-review-and-approval-process-in-canada-an-eguide/">https://spharm-inc.com/the-drug-review-and-approval-process-in-canada-an-eguide/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-01-10">(accessed on 10 January 2020)</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig id="molecules-25-04821-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Illustration of concepts associated with the development of cannabis-related pharmaceutical drugs. Cannabis-inspired drugs, cannabinergic drugs, or cannabis-based drugs are to be developed while interaction(s) between phytocannabinoids or synthetic cannabinoids and the endocannabinoid system should be examined. Drug review and approval process steps should be taken.</p></caption><graphic xlink:href="molecules-25-04821-g001"/></fig><table-wrap id="molecules-25-04821-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-25-04821-t001_Table 1</object-id><label>Table 1</label><caption><p>Cannabis-inspired or -based medicines available today and their pharmaceutical status. FDA, Food and Drug Administration; THC, &#x00394;9-tetrahydrocannabinol; CBD, cannabidiol; CBN, cannabinol; CYP, Cytochrome P450; EU, European Union; UGT, uridine 5&#x02032; diphospho-glucuronosyltransferase.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Basic Formulation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Studies</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Proved Efficacy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Key Limiting Toxicity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Recommended Dosage </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug&#x02013;Drug Interactions Reported</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approval</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td colspan="10" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Drugs of one molecule</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MARINOL<sup>&#x000ae;</sup> (GW Pharmaceuticals, Cambridge, UK)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Appetite stimulation; antiemetic associated with cancer chemotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dronabinol (synthetic THC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 mg/day<break/>or 30 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Appetite stimulation: 2.5 mg twice daily; antiemetic: 5 mg 3&#x02013;4 times daily</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B16-molecules-25-04821" ref-type="bibr">16</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EPIDIOLEX<sup>&#x000ae;</sup> (GW Pharmaceuticals)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lennox&#x02013;Gastaut syndrome and Dravet syndrome in patients </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plant derived CBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 mg/kg/day</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#x02013;20 mg/kg/day </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP1A2, CYP2B6<break/>substrates, uridine 5&#x02019; diphospho-glucuronosyltransferase 1A9 (UGT1A9) and UGT2B7. <break/>CYP2C8 and CYP2C9 substrates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B17-molecules-25-04821" ref-type="bibr">17</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SYNDROS<sup>&#x000ae;</sup> (Benuvia Therapeutics Inc, Chandler, AZ, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anorexia; nausea and vomiting associated with cancer chemotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dronabinol (synthetic THC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 mg/day</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2 mg/day </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropsychiatric adverse reactions; hemodynamic instability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B18-molecules-25-04821" ref-type="bibr">18</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CESAMET<sup>&#x000ae;</sup> (Valeant Pharma Int, Laval, QC, Canada)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nausea and vomiting induced<break/>by cancer chemotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nabilone<break/>(synthetic THC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 mg/day</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diazepam 5 mg; sodium secobarbital 100 mg;<break/>alcohol (absolute) 45 mL; codeine 65 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B19-molecules-25-04821" ref-type="bibr">19</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">INM-755 cream (Inmed pharma, Vancouver, BC, Canada)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin diseases and wounds; epidermolysis bullosa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria <italic>Escherichia coli</italic> fermentation derived from one rare CBN (Cannabinol)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes Phase 1&#x02013;2 ongoing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses of INM-755 cream are currently being tested</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-molecules-25-04821" ref-type="bibr">20</xref>]</td></tr><tr><td colspan="10" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Drugs of combinatoric formulations</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SATIVEX<sup>&#x000ae;</sup> Oromucosal spray (GW Pharmaceuticals)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain relief</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plant-derived CBD:THC and terpenes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90 mg/day</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#x02013;60 mg/day</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reversible inhibitor of CYP3A4, 1A2, 2B6, 2C9, and 2C19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EU, Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-molecules-25-04821" ref-type="bibr">21</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="molecules-25-04821-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-25-04821-t002_Table 2</object-id><label>Table 2</label><caption><p>The general drug review and approval process steps. DDIs, drug&#x02013;drug interactions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Activities</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Initial drug research</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Discovering and identifying various chemical and biological substances or other products on the way toward developing a drug; testing for activity, efficacy, toxicity, and ultimately gathering preliminary information on its effectiveness and safety. If the results are promising, researchers proceed to the next stage of development.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2. Preclinical studies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administration of the drug to selected species of animals (in vivo) or cells (in vitro). The drug must be shown to cause no serious harm (toxicity) at the doses required to have an effect either in a single compound or in DDIs. If results from these initial studies are promising and further tests show acceptable safety levels and clear or potential efficacy, then the next step would be to submit a clinical trial application.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3. Clinical trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The results of clinical trials conducted with humans are key components of the review process by the regulatory agency. The purpose of a trial is to gather clinical information about a drug&#x02019;s effectiveness and safety, determine best dosing/usage in humans, evaluate any adverse drug reactions and DDIs, and compare results to already existing treatments for the same disease or condition or to placebo when no treatment already exists for the aimed pathology (when ethically possible). The information gathered from these trials is then included in the dossiers to be reviewed by the relevant agencies.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4. Drug approval process</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">If results of all the preclinical studies and the clinical trials show that a drug&#x02019;s potential therapeutic benefit outweighs its risks (side effects, toxicity, etc.), and the chemistry and manufacturing dossier is complete, then the sponsor may decide to file a new drug submission (NDS) with the appropriate regulatory agency in order to be granted authorization to sell the drug in the country.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5. After approval</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The regulatory agency requires a sponsor to ensure that the use of its drug is done under the terms of its market authorization. In addition, life cycle management activities (post-approval submissions, for new indications, new dosage forms, new strengths, manufacturing changes, etc.) are required to ensure the maintenance of the product license with its related improvements. In summary, sponsors need to ensure its continued compliance with the food and drug regulations while their products are on the market.<break/>On the other hand, the regulatory agency monitors drug information and adverse drug reaction reporting, conducts market surveillance, investigates complaints, and manages recalls if necessary, amongst other things. </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6. Additional regulations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">There are also more processes and regulations to follow and consider before, during, or after the review process, and before the drug is officially marketed, distributed, and sold in a country. Topics included licensing, warehousing, wholesale distribution rules, and the Drug Establishment License (DEL), as well as regulations around distribution to consumers, regulations around the marketing and advertising activities, provincial requirements, and health insurance funding rules, among others.</td></tr></tbody></table></table-wrap></floats-group></article>